Suppr超能文献

不可切除的晚期肝细胞癌侵犯肝内大血管患者的放射治疗:疗效和结果

Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes.

作者信息

Tanaka Yoshiaki, Nakazawa Takahide, Komori Shouko, Hidaka Hisashi, Okuwaki Yusuke, Takada Juichi, Watanabe Masaaki, Shibuya Akitaka, Minamino Tsutomu, Yamamoto Hajime, Kokubu Shigehiro, Hayakawa Kazushige, Koizumi Wasaburo

机构信息

Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Tokyo, Japan.

出版信息

J Gastroenterol Hepatol. 2014 Feb;29(2):352-7. doi: 10.1111/jgh.12333.

Abstract

BACKGROUND AND AIM

To examine the efficacy and outcomes of radiotherapy (RT) in patients who have hepatocellular carcinoma with invasion to intrahepatic large vessels (IHLVs).

METHODS

Sixty-seven patients who had advanced hepatocellular carcinoma with invasion to IHLVs received three-dimensional conformal RT. IHLV invasion was associated with portal venous tumor thrombosis in 40 patients, tumor thrombosis involving the hepatic vein in 17, and both findings in 10. A daily radiation dose of 1.8-2 Gy was administered using 6 or 10 MV X-rays to deliver a total dose of 30-56 Gy.

RESULTS

The overall objective response rate (complete response plus partial response) was 45% (n = 30). The median survival time was 13.7 months in the responder group and 5.9 months in the nonresponder group. An objective response was observed in 28 (56%) of 50 patients with Child-Pugh (C-P) class A and in 2 (12%) of 17 patients with C-P class B. Hepatic function of C-P class A was an independent factor for both RT responder and overall survival on Cox regression analysis (hazard ratio = 9.5, 95% confidence interval = 1.97-46.2, P = 0.005; and hazard ratio = 0.39, 95% confidence interval = 0.2-0.77, P = 0.007, respectively).

CONCLUSION

RT is an effective treatment option without serious adverse events. RT should be considered for the patients with better hepatic function who have invasion to IHLVs.

摘要

背景与目的

探讨放射治疗(RT)对侵犯肝内大血管(IHLV)的肝细胞癌患者的疗效及预后。

方法

67例侵犯IHLV的晚期肝细胞癌患者接受三维适形放疗。40例患者的IHLV侵犯与门静脉癌栓有关,17例涉及肝静脉癌栓,10例两者均有。采用6或10MV X线,每日放疗剂量为1.8 - 2Gy,总剂量为30 - 56Gy。

结果

总客观缓解率(完全缓解加部分缓解)为45%(n = 30)。缓解组的中位生存时间为13.7个月,未缓解组为5.9个月。50例Child-Pugh(C-P)A级患者中有28例(56%)出现客观缓解,17例C-P B级患者中有2例(12%)出现客观缓解。Cox回归分析显示,C-P A级肝功能是RT缓解和总生存的独立因素(风险比分别为9.5,95%置信区间为1.97 - 46.2,P = 0.005;风险比为0.39,95%置信区间为(0.2 - 0.77),P = 0.007)。

结论

RT是一种有效的治疗选择,且无严重不良事件。对于侵犯IHLV且肝功能较好的患者,应考虑RT治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验